India ruling on cancer drug to be challenged

Order forcing Bayer to license its product to local company has huge repercussions for pharmaceutical giants.



    A patent ruling in India is forcing German drug giant Bayer to license its anti-cancer medicine to an Indian company, Natco.

    This will slash the price of the drug in India by up to 97 per cent. Bayer insists it will fight the ruling although Natco will be paying it six per cent royalty on the sales of Nexavar.

    This is the first time such a ruling has been made in India and has massive repercussions for drug giants and their patents globally.

    Prerna Suri reports from New Delhi.

    SOURCE: Al Jazeera


    YOU MIGHT ALSO LIKE

    Assad to Putin: Thank you for 'saving our country'

    Assad to Putin: Thank you for 'saving our country'

    Russian and Syrian presidents meet to discuss strategy against 'terrorism' and political settlement options.

    Is Saudi Arabia becoming a danger to the region?

    Is Saudi Arabia becoming a danger to the region?

    We talk to US Congressman Ro Khanna about power politics and debate Mohammed bin Salman's new strategy for the Kingdom.

    Gender violence in India: 'Daughters are not a burden'

    Gender violence in India: 'Daughters are not a burden'

    With female foeticide still widespread, one woman tells her story of being mutilated for giving birth to her daughters.